CHANGING MANAGEMENT OF INFECTIONS IN THE IMMUNOCOMPROMISED

Shorter antibiotic courses in the immunocompromised: the impossible dream?

Hannah Imlay, Nicholas C Laundy, Graeme N Forrest, Monica A Slavin

2023-02-01

BACKGROUND: A growing number of studies have demonstrated similar outcomes with shorter courses of antibiotics for bacterial infec..

Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center

Julian Lindsay, Elizabeth M Krantz, Jessica Morris, Ania Sweet, Frank Tverdek, Avadhut Joshi, Rosa Yeh, Joshua A Hill, Matthew Greenwood, Sharon C-A Chen, David CM Kong, Monica Slavin, Steven A Pergam, Catherine Liu

2022-07-30

Voriconazole (VCZ) was one of the first mold-active triazoles available; however, its current use among high-risk hematology popul..

Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation

Julian Lindsay, Matthew Greenwood, Jad Othman, Sharon C-A Chen, David CM Kong, Steven A Pergam, Catherine Liu, Monica A Slavin

2022-04-15

Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia

Gabrielle M Haeusler, Alexandra L Garnham, Connie Sn Li-Wai-Suen, Julia E Clark, Franz E Babl, Zoe Allaway, Monica A Slavin, Francoise Mechinaud, Gordon K Smyth, Bob Phillips, Karin A Thursky, Marc Pellegrini, Marcel Doerflinger

2022-01-01

OBJECTIVES: Febrile neutropenia (FN) is a major cause of treatment disruption and unplanned hospitalization in childhood cancer pa..

Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes

Julian Lindsay, Jad Othman, Madeleine R Heldman, Monica A Slavin

2021-12-01

PURPOSE OF REVIEW: Management of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV PTLD) is complex, involving r..

Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021

Christina C Chang, Christopher C Blyth, Sharon C-A Chen, Anna Khanina, C Orla Morrissey, Jason A Roberts, Karin A Thursky, Leon J Worth, Monica A Slavin

2021-11-01

This article introduces the fourth update of the Australian and New Zealand consensus guidelines for the management of invasive fu..

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

Julian Lindsay, Jad Othman, Yvonne Kong, Annie Yip, Sebastiaan Van Hal, Stephen Larsen, Christian Bryant, John Gibson, Ian Kerridge, Keith Fay, William Stevenson, Chris Arthur, Sharon CA Chen, David CM Kong, Matthew Greenwood, Steven A Pergam, Catherine Liu, Monica A Slavin

2021-11-01

BACKGROUND: Itraconazole (ITZ) is an effective agent when used as primary invasive fungal disease (IFD) prophylaxis, but is limite..

Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant

Julian Lindsay, Jad Othman, Michelle K Yong, David Ritchie, Lynette Chee, KimHeng Tay, Shio Yen Tio, Ian Kerridge, Keith Fay, William Stevenson, Chris Arthur, Sharon C-A Chen, David CM Kong, Matthew Greenwood, Steven A Pergam, Catherine Liu, Monica A Slavin

2021-09-12

BACKGROUND: The use of antithymocyte globulin (ATG) in allogeneic hematopoietic cell transplant (HCT) is associated with an increa..

Infection-Related Mortality in Adults and Children Undergoing Allogeneic Hematopoietic Cell Transplantation: An Australian Registry Report

Julian Lindsay, Ian Kerridge, Leonie Wilcox, Steven Tran, Tracey A O'Brien, Matthew Greenwood, Sharon C-A Chen, David CM Kong, Steven A Pergam, Catherine Liu, Monica A Slavin

2021-08-24

Infection-related mortality (IRM) is the most common non-relapse-related cause of death reported after allogeneic hematopoietic ce..

The Role of In Vivo and Ex Vivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions

Ana Copaescu, Effie Mouhtouris, Sara Vogrin, Fiona James, Kyra YL Chua, Natasha E Holmes, Abby Douglas, Monica A Slavin, Heather Cleland, Celia Zubrinich, Ar Kar Aung, Michelle SY Goh, Elizabeth J Phillips, Jason A Trubiano

2021-05-06

BACKGROUND: The use of in vivo and ex vivo diagnostic tools for delayed immune-mediated adverse drug reactions is currently ill de..

The impact of pharmacist-led antifungal stewardship interventions in the hospital setting: a systematic review

Anna Khanina, Kelly A Cairns, David CM Kong, Karin A Thursky, Monica A Slavin, Jason A Roberts

2021-04-20

Aim: To summarise the evidence on pharmacist-led antifungal stewardship (AFS) programs in the hospital setting and to evaluate the..

Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?

Gemma Reynolds, Gabrielle Haeusler, Monica A Slavin, Benjamin Teh, Karin Thursky

2021-03-24

PURPOSE: Contention surrounds how best to screen patients for latent and undiagnosed infection prior to cancer treatment. Early tr..